GlobeNewsWire · KTTA · October 23, 2026

Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026

Get the app for more

Explore stock news, insights and company research.